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Abstract
Gene therapy offers promise for the treatment of both inherited and acquired diseases
through the introduction of genetic material into target cells. The primary challenge for
gene therapy is to develop a safe and efficient method for the delivery of therapeutic
genetic material to the specific intracellular target. Non-viral carriers have received
significant attention because of their potential to overcome the limitations of viral-based
systems. However, their relatively low efficacy is a major obstacle to their clinical
application. A thorough understanding of the key factors affecting the gene delivery
process will provide clues on how to develop more effective carriers. This thesis focuses
on the role of the carrier and the endocytic pathway in non-viral gene delivery, and also
suggests improvements in the experimental methodology that would make it possible to
obtain more reliable results in nanoparticle uptake studies.
More effective carriers for gene delivery are very much needed. We tested the novel
pentaspheric lysine-based dendrimer and its analog, modified with fatty acid residues, for
their gene delivery capacity. We demonstrated that despite their relatively low in vitro
transfection efficacy, lysine dendrimers have good plasmid DNA (pDNA) binding and
protective properties, and can therefore be used as the basis for the development of more
effective carriers.
A detailed understanding of the cellular kinetics of gene delivery systems is critical to
the further development of more effective carriers. We studied the impact of the carrier
and of the endocytic pathway on cell uptake and the intracellular processing of genetic
material (pDNA). The highly sensitive method of quantitative real-time PCR was applied
to the study of the intracellular kinetics of pDNA introduced by the cationic polymer PEI,
cationic lipid DOTAP, and CaP precipitates at multiple time points after transfection. The
results obtained indicate that the carrier affects the cell uptake and the intracellular
kinetics, and therefore predetermines the main transfection-limiting step. Furthermore, we
demonstrated the important role of the post-nuclear processes in efficient non-viral gene
delivery.
The impact of a specific endocytic pathway was studied by the inhibition of either the
clathrin- or dynamin-mediated endocytosis. Selective blockage of endocytosis was
achieved by two approaches, namely the genetically manipulated cell lines and the
chemical inhibitors of endocytosis. Analysis of the intracellular kinetics of pDNA in the
genetically blocked cells revealed that neither the amount of pDNA taken up by the cell,
nor the intracellular pDNA elimination, but the amount of pDNA delivered to the nucleus
was indicative of the significance of the particular pathway in the resulting efficacy of the
carrier. A comparison of chemical and genetic means for blocking endocytosis revealed
the limitations of both these methods. A careful optimization of the method and the use of
several alternative approaches is recommended in order to obtain more reliable data.
We suggest that the characterization of in vitro cell models for the expression and
activity of specific endocytic pathways (endocytic profiling) would facilitate the
interpretation of the data obtained in nanoparticle uptake studies. Endothelial and
epithelial cells are widely utilized in such studies because they form substantial barriers en
route from the administration site to the target tissue. We performed endocytic profiling of
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the epithelial CaCo-2 cells and the endothelial hCMEC/D3 cells at different stages of
differentiation. The expression of genes involved in specific endocytic pathways was
analysed at the mRNA level by quantitative real-time PCR, and at the protein level by
Western blotting. The endocytic activities of the cells were analyzed by flow cytometry.
We concluded that the mRNA expression of the endogenous proteins involved in
particular endocytic pathways can be indicative of the expression and activity of these
pathways. Furthermore, we showed that the differentiation status of the cells affects their
endocytic activity, and must therefore be taken into account when designing nanoparticle
uptake and transcellular permeability experiments. A comparison of the endocytic profiles
of cell lines with primary cells revealed clear discrepancies, pointing to the importance of
careful selection of in vitro models for endocytosis-related studies.
Overall, our study has improved the mechanistic understanding of the non-viral gene
delivery process. We have described how the carrier and endocytic pathway both affect
intracellular kinetics and the efficacy of gene transfer. Furthermore, we have demonstrated
the importance of method optimization and the endocytic profiling of in vitro cell models
in improving the quality of the obtained data.
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1 Introduction
Conventional drugs often treat symptoms, but not the cause of the disease. Recent
advances in molecular biology allow us to understand the molecular mechanisms of many
diseases. The vast majority of these diseases are caused by a disturbance in normal protein
production. The identification of the genes coding for various proteins and the genes
involved to regulation of protein production has opened possibilities for more specific
therapeutic approaches. The principle of gene therapy is to cure the disease by introducing
genetic material into the target cells. The strategies include the introduction of DNA in
order to produce therapeutic protein, or the introduction of siRNA, miRNA or antisense
oligonucleotides to knock-down the expression of the gene involved in the diseased
condition. Gene therapy offers promise for the treatment of both inherited and acquired
diseases, including those which are currently regarded as incurable (Verma, Weitzman
2005). By June 2014, worldwide over 2000 gene therapy clinical trials had been approved,
as either ongoing or completed (The Journal of Gene Medicine Clinical Trial site). The
first gene therapy products have been approved as gene medicines, including Gendicine in
China (2003) as an anti-cancer treatment and Glybera in Europe (2012) for the treatment
of lipoprotein lipase deficiency ˗ a rare inherited disease (Wirth, Parker & Yla-Herttuala
2013).
The biopharmaceutical properties of genetic material are poor. Its large size and
negative charge renders it unable to cross biological barriers and prone to degradation
and/or clearance from the body.Therefore, there is a need for an excipient termed a carrier
or vector, which would be able to protect and specifically deliver the genetic material to
the target site. Currently, more than 65% of all gene therapy clinical trials involve viral-
based carriers (The Journal of Gene Medicine Clinical Trial site, updated June 2014); all
currently approved gene therapy products are viral-based (Wirth, Parker & Yla-Herttuala
2013). However, several cases of cancer have developed in patients who received viral-
based gene therapy treatment in clinical trials, raising important safety concerns (Ginn et
al. 2013). Further limitations of the viral systems include their ability to raise
immunological response, broad tropism to various cell types, and low loading capacity.
Non-viral carriers are synthetic or natural substances which are able to bind and condense
genetic material into nanoparticles and deliver it into cells. They provide easier, cheaper,
and, most importantly, safer alternatives to viral systems (Niidome, Huang 2002 ; Pezzoli
et al. 2012). Over the last decade, thousands of compounds have been tested for their gene
delivery capacities. However, low delivery efficacy remains a serious problem, preventing
the wider introduction of non-viral gene delivery systems into clinical trials.
To facilitate the development of more effective carriers, a thorough understanding of
the delivery process is essential. Cell internalization is especially important, as target sites
for gene-based therapeutics are intracellular. Gene delivery systems enter cells mainly by
endocytosis, the process naturally used by cells for the uptake of solutes and particles
(Iversen, Skotland & Sandvig 2011; Nguyen, Szoka 2012). Many endocytic pathways are
known, and more are being discovered. The endocytic pathway is believed to define the
intracellular trafficking and the final destination of the endocytosed entity, including the
trafficking to the endolysosomal compartment for degradation, recycling to the cell
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surface, and transport to the other side of the cell (transcytosis). Therefore, the
identification of the endocytic pathways used by the gene delivery systems of different
structures provides the basis for the development of more effective carriers. This type of
study is methodologically very challenging, as the endocytic pathway of the gene delivery
system is strongly affected by multiple factors, including the physico-chemical properties
of the particle and the cell type (Vercauteren et al. 2012). To improve the reliability of the
obtained data, comparative studies using different methods are required. Another
important prerequisite for progress in the field is the use of suitable cell models which
have been properly characterized in terms of their operating endocytic pathways.
The aim of this thesis is to improve the understanding of the role of the carrier and of
the endocytic pathway in non-viral gene delivery. The problem is dealt with from several
perspectives: testing of novel carriers for their gene delivery capacity; studying the
relation between structure of the carrier, its endocytic pathway and its gene delivery
efficacy; justification of methods and characterization of the in vitro cell models used to
study the role of the endocytic pathway in gene delivery.
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2 Review of the literature
2.1 Non-viral gene delivery systems
Thousands of molecules, both of natural origin and chemically synthesized, have been
tested for their gene delivery properties. The vast majority of gene delivery systems have
sizes in the submicron range and can therefore be classified as nanoparticles (NPs). The
main classes of non-viral gene delivery systems include:
 polymer-based systems (polymeric NPs, polymerosomes, polymeric micelles)
 lipid-based systems (liposomes, nanoemulsions, solid lipid NPs)
 inorganic systems (calcium phosphate, gold and silica NPs, carbon nanotubes, etc.)
 hybrid particles (combinations of the aforementioned types)
Typically, molecules tested as potential non-viral gene delivery carriers are positively
charged, in order to be able to spontaneously bind the negatively-charged genetic material.
In general, an excess of the carrier is used to generate particles with a small size and
positive surface charge. A size of about 100 nm seems to be the most favourable for cell
uptake, although bigger particles (up to several μm) can be taken up, especially by cell
types capable of phagocytosis (Hillaireau, Couvreur 2009). The positive surface charge
facilitates the binding to the negatively charged cell membrane. Nevertheless, some
examples of efficient gene delivery mediated by overall neutral or negatively charged NPs
have also been reported (Patil, Rhodes & Burgess 2004; Green et al. 2007).
The performance of the carrier has often been improved by chemical modification with
functional groups. For example, the attachment of polyethylene glycol (PEG) is widely
used to increase water solubility and blood circulation time, to decrease renal clearance,
and to reduce the immunogenicity of the gene delivery system (Ikeda, Nagasaki 2014).
The active targeting of specific cell types can be achieved by the attachment of ligands
that are recognized by particular cellular receptors. Examples of ligands successfully used
for the targeting of gene delivery systems include transferrin (Dufes, Al Robaian &
Somani 2013), folate (Zhao, Li & Lee 2008), epidermal growth factor (Ye, Gao & Cai
2010; Taylor, Furnari & Cavenee 2012), and many others.
In the following review, polymeric NPs and liposomes are discussed in more detail
because these carriers have been included in the studies reported in this thesis.
2.1.1 Polymeric nanoparticles
Cationic polymers are able to condense genetic material into small complexes called
polyplexes. Typical polyplexes are 10-100 nm in size, which is favourable for gene
delivery to non-phagocytic cells. Polyplexes can be globular, toroid or rod-like in
morphology depending on the type of polymer. Based on their molecular structure,
cationic polymers can be divided into linear and branched (Figure 1, A,B). Polymer-based
systems have the advantage of high carrying capacity and molecular diversity. Their
physicochemical properties, such as molecular weight, polydispersity, composition, and
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density of side chains, can be modulated in order to achieve better delivery efficacy,
biocompatibility, and improved safety (Pezzoli et al. 2012).
Both synthetic polymers, such as polyethylenimine (PEI) and polyphosphoesters, and
natural polymers, such as proteins, peptides, and polysaccharides, have been used for gene
delivery. The most studied and promising polymers include the biodegradable polyesters
(PLGA and PLA) (Avgoustakis 2004), PEI (Lungwitz et al. 2005), chitosan
(biodegradable derivative of chitin) (Buschmann et al. 2013) and the dendrimers. The
dendrimers are discussed in more detail in the next chapter.
Figure 1. Structures of carriers used for gene delivery: linear polymer (A), irregularly branched
polymer (B), dendrimer (C), and liposome (D).
2.1.2 Dendrimers
Dendrimers are globular, nano-sized macromolecules with regularly branched “arms”
originating from a central core (Figure 1, C). The number of repeating branch units is
referred as the “number of spheres”, or the “generation” of the dendrimer. The dendritic
structure provides several advantages over conventional linear and irregularly branched
structures. The controlled synthesis of dendrimers results in low polydispersity, and
therefore more reproducible pharmacokinetic behavior. The high density of the surface
groups provides various possibilities for surface functionalization in order to improve
water solubility, reduce toxicity, target a specific tissue or cell type, etc. Due to the well-
defined structure of the dendritic molecule, surface functionalization can be performed in
a more controlled manner (Gillies, Frechet 2005; Nanjwade et al. 2009).
In recent years, many types of dendrimers have been synthesized and tested as
potential gene delivery carriers. The gene delivery properties of the dendrimer are highly
dependent on the generation number and the surface functionalization, as well as on the
target cell type. Polyamidoamine (PAMAM) dendrimers, introduced by Tomalia et al. in
1984 (Tomalia et al. 1984), are probably the mostt studied ones, and some of them have
shown efficient delivery of DNA, siRNA and oligonucleotides, both in vitro and in vivo
(Xu, Wang & Pack 2010; Wu, Huang & He 2013). Polypropyleneimine dendrimers were
demonstrated to induce intratumoral transgene expression after intravenous administration
(Dufès et al. 2005) and to be efficient in siRNA delivery (Wu, Huang & He 2013).
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Significant effort has been devoted to the development of biodegradable dendrimers. For
example, some polyglycerol-based (Fischer et al. 2010) and peptide-based (Luo et al.
2012) dendrimers have been shown to have potential in gene delivery applications
[reviewed in (Luo et al. 2014)].
2.1.3 Liposomes
Liposomes are spherical particles formed by one or more lipid bilayers with an
aqueous central core (Figure 1, D). Liposomes have been shown to be efficient in the
delivery of DNA, siRNA and oligonucleotides, both in vitro and in vivo (Fenske, Cullis
2008), and they are the most frequently used non-viral gene delivery systems in gene
therapy clinical trials (Ginn et al. 2013). The main advantages of liposomes as gene
delivery carriers are their low toxicity and high carrying capacity.
The liposomes used in gene delivery are typically composed of a cationic lipid
responsible for the binding of the genetic material, and a neutral lipid, often called a
“helper lipid”, that improves stability and gene delivery efficacy. DOPE
(dioleoylphosphatidylethanol-amine) and cholesterol are examples of the most frequently
used helper lipids. Cationic lipids consist of a cationic headgroup and a hydrophobic
domain connected by a linker. The properties of the head group, rather than those of the
hydrophobic domain, are believed to be critical for gene transfer (Horobin, Weissig 2005).
Examples of widely used cationic lipids include DOTAP (1,2-dioleoyloxy-3-
(trimethylammonio)propane), DOTMA (N-[1-(2,3-dioleyl)propyl]-N,N,N-
trimethylammonium chloride) and DOGS (dioctadecylamidoglycyl-spermine) (Balazs,
Godbey 2011; Tros de Ilarduya, Sun & Duzgunes 2010).
Complexes consisting of cationic liposomes and nucleic acids are usually formed by
self-assembly and are called lipoplexes. The lipoplex structure depends on the liposome
lipid composition. Multilamellar (composed of DNA layers alternating with cationic lipid
bilayers), inverted hexagonal, and other structures have been reported (Tros de Ilarduya,
Sun & Duzgunes 2010).
2.2 Barriers to non-viral gene delivery
2.2.1 Extracellular barriers
In order to reach the target tissue/cell after in vivo administration, non-viral gene
delivery systems need to pass multiple barriers created by extracellular biomolecules, non-
target tissues, and cells (Wiethoff, Middaugh 2003; Uchegbu, Schatzlein 2010). The
number of barriers to be overcome depends on the administration route (Figure 2).
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Figure 2. Main extracellular barriers in the way of therapeutic nanoparticles administered by
different routes. It must be noted that target cells can also be endothelial, epithelial or blood cells,
depending on the pathological condition to be treated.
Direct injection into target tissue, such as a tumor, is a widely used administration
route for gene delivery systems as it brings them into immediate proximity to the target
cells (Figure 2). However, the carrier needs to shield the genetic material efficiently from
degradation by the extracellular nucleases present in the tissue. Moreover, the delivery
system must avoid interaction with non-target cells and entrapment by the extracellular
matrix including the proteoglycans. Negatively charged glycosaminoglycan chains of
proteoglycans may bind positively charged gene delivery complexes and limit their
mobility towards the target cells or cause premature release of the cargo (Ruponen et al.
2003).
Many in vivo tissues are not accessible for direct injection and can only be reached via
intravascular administration. Once in the blood, delivery systems come into contact with
nucleases, blood lipids, and negatively charged serum proteins such as albumin,
fibronectin, complement, immunoglobulins, and apolipoproteins. Adsorption of proteins
and lipids on the surface of the gene delivery system results in the formation of a so-called
“biomolecular corona”. The composition of the biomolecular corona is dependent on both
the NP properties and the composition of the biological environment and is subject to
dynamic changes (Monopoli et al. 2012; Pearson, Juettner & Hong 2014). The
biomolecular corona has been shown to critically affect the delivery properties of NPs,
including their biodistribution, circulation time, targeting, and toxicity. For example, in
the case of intravascular administration, adsorption of immunoglobulins and the
complement on the NP surface can cause their recognition and rapid clearance from the
circulation by the immune system (Pearson, Juettner & Hong 2014). Proteins on the
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surface of targeted NPs were shown to perturb their binding to the target cells by shielding
the receptor-specific ligands (Salvati et al. 2013). Biomolecular corona may also lead to
premature cargo release (Azagarsamy, Yesilyurt & Thayumanavan 2010). Furthermore,
delivery systems can unspecifically bind, enter, and be degraded within the blood and
other non-target cells. The most common strategy to reduce unspecific interactions is to
coat the gene delivery systems with stabilizing/shielding agents, such as PEG (Wiethoff,
Middaugh 2003; Pezzoli et al. 2012) or albumin. For example, in the recent study of Peng
and co-authors, a preformed albumin protein corona was shown to increase circulation
time and reduce the toxicity of intravenously injected NPs (Peng et al. 2013).
The vascular endothelium creates an important extracellular barrier for systemically
administrated delivery systems. Intracellular spaces between the endothelial cells are
typically sealed with junctional complexes, including both tight junctions and adherens
junctions. In the liver and spleen, the vascular endothelium has openings, or fenestrae,
which allow enhanced paracellular permeation and the accumulation of nanoparticulate
delivery systems in these organs (Garnett, Kallinteri 2006). Endothelia of other tissues,
especially of the central nervous system, are continuous, tight, and therefore impermeable
for the positively charged and relatively large in size gene delivery systems.
Junctional complexes are also very tight in epithelial tissues, forming a substantial
extracellular barrier for delivery systems administered extravascularly, for example by
transdermal, oral, or pulmonary administration routes.
To cross the epithelial/endothelial barriers by a paracellular pathway, the integrity of
the adhesive junctions has to be perturbed. Intracellular junctions are known to be
disrupted in some pathological conditions, for example in inflammation (Kumar et al.
2009; Ivanov, Parkos & Nusrat 2010). Disruption of intracellular junctions can also be
achieved by applying permeation enhancers. For example, PAMAM dendrimers have been
shown to have intrinsic permeation enhancer activity (Sadekar, Ghandehari 2012). In the
absence of permeation enhancers, the only pathway by which gene delivery systems can
overcome healthy epithelial/endothelial barriers is by transcytosis, which is discussed in
greater detail in chapter 2.4.
2.2.2 Cell entry and intracellular barriers
After reaching the target cell, the gene delivery system needs to efficiently cross the
plasma membrane, composed of a lipid bilayer, and then bypass multiple intracellular
barriers (Figure 3). By now, it is well established that the main route for the uptake of
NPs, including gene delivery systems, is endocytosis (Iversen, Skotland & Sandvig 2011;
Treuel, Jiang & Nienhaus 2013). Typically, endocytosis occurs after cell surface binding,
which can be either specific (if the surface of the gene delivery system is decorated by the
ligand targeted to a certain receptor), or non-specific (hydrophobic and electrostatic
interactions). NPs may also penetrate living cell membranes by generating ruptures, which
often cause undesirable cytotoxic effects (Treuel, Jiang & Nienhaus 2013). However,
membrane disruption can be reduced, or even avoided, by modulation of the surface
structure and/or charge density (Verma et al. 2008; Lin et al. 2010; Wang et al. 2012).
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Cytoplasm appears to be a considerable intracellular barrier, as it is crowded with
macromolecules, is highly structured due to the dense cytoskeleton, and also contains
active nucleases. Diffusion of genetic material through the cytoplasm is very limited due
to its large size (Lukacs et al. 2000). It has been reported that both naked plasmid DNA
(pDNA) and gene delivery systems (Vaughan, Dean 2006; Hasegawa, Hirashima &
Nakanishi 2001; Suh, Wirtz & Hanes 2003) can be trafficked through the cytoplasm
towards the nucleus along microtubules. With gene delivery systems, most of the
microtubule-mediated transport occurs while still within the endosomes (Suh, Wirtz &
Hanes 2003; Akita et al. 2010).
For small RNAs and oligonucleotides, cytoplasm is the final destination, whereas
DNA has to penetrate into the nucleus in order to be transcribed (Figure 3). The nuclear
envelope has been proposed as being one of the most substantial barriers. The nuclear
envelope is fenestrated with nuclear pores that limit the passive diffusion of molecules
with sizes larger than 50 kDa (Vaughan, DeGiulio & Dean 2006). Being relatively large in
size, gene delivery systems, or released DNA, can enter the nucleus passively during cell
division when the nuclear envelope is disassembled. This has been suggested as a major
way for the entry of pDNA into the nuclei of rapidly dividing cells, such as immortalized
cell lines (Brunner et al. 2000; Grosse et al. 2006). An alternative strategy is active
transport through the nuclear pores utilizing the endogenous nuclear import machinery.
Molecules modified with the nuclear targeting signal (NLS) can be recognized and
transported into the nucleus by the nuclear pore complex (Vaughan, DeGiulio & Dean
2006).
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Figure 3. Main intracellular steps and barriers to non-viral gene delivery.
The release of genetic material from the carrier is another important intracellular
barrier (Figure 3). The mechanism and intracellular location of this process is carrier-
dependent. It is believed that lipoplexes release genetic material upon fusion with the
endosomal membrane, whereas polyplexes escape from the endosomes intact and release
DNA either in the cytoplasm or inside the nucleus. In general, binding by the carrier
should be strong enough to prevent enzymatic degradation of the genetic material by
intracellular nucleases, yet allow its further processing such as transcription. Indeed,
insufficient release of DNA from a cationic carrier has been shown to be responsible for
strikingly reduced transcription efficiency after gene delivery by the lipid-based carrier
Lipofectamine in comparison to adenovirus (Hama et al. 2007).
Knowledge of the impact of the carrier on the functions of the cell is still very limited.
It can be assumed that the positively charged carrier can interact with endogenous
molecules causing toxicity and interfering with various intracellular processes including
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the translation of the genetic material (Hama et al. 2007). One way to circumvent this
problem is to use biodegradable carriers.
2.3 Endocytic pathways and their role in gene delivery
Endocytosis is a general term for the formation of membrane vesicles on the cell
plasma membrane and the subsequent internalization of these vesicles. Endocytosis
constantly occurs in living cells, serving their nutrient uptake, receptor signaling,
regulation of cell shape, and volume. In certain cell types, endocytosis is involved in
transcellular transport and pathogen removal (Doherty, McMahon 2009). The endocytic
pathway is very important with respect to NP-mediated drug and gene delivery as it
defines the intracellular routing, cytoplasmic release, final destination, and therefore the
efficacy of the delivery system (Khalil et al. 2006a; Vercauteren et al. 2012).
Endocytosis is typically classified into phagocytosis, used for the uptake of large
particles and mainly restricted to specialized mammalian cells, and pinocytosis, used for
uptake of fluids and small particles and occurring in all cell types. Based on the proteins
involved, pinocytosis can be further subdivided into macropinocytosis, clathrin-mediated
endocytosis, and a diverse group of clathrin-independent pathways, the majority of which
have been discovered only recently and are therefore relatively poorly characterized
(Doherty, McMahon 2009; Sandvig et al. 2011). Alternatively, endocytic pathways can be
classified based on their relation to lipid rafts. Lipid rafts are “small (10-200 nm),
heterogeneous, highly dynamic, sterol- and sphingolipid-enriched domains that
compartmentalize cellular processes” (Pike 2006). Some types of endocytosis are believed
to be restricted to certain types of lipid rafts. Therefore, lipid raft-based classification can
be helpful in identifying the specific regulators of endocytic pathways as well as in
selecting the specific inhibitors for particular pathways (El-Sayed, Harashima 2013).
Other important characteristics of the endocytic pathways include the involvement of actin
cytoskeleton and their dependence on dynamin ˗ a large GTPase implicated in the fission
of the endocytic vesicle from the plasma membrane. The main features of each endocytic
pathway are represented in Figure 4. Their mechanisms and role in gene delivery will be
discribed in greater detail in the following sections.
2.3.1 Phagocytosis
Phagocytosis refers to the uptake of large particles, of up to several micrometers in
diameter. Being an important defence mechanism against foreign substances, phagocytosis
is usually confined to specific cells of the immune system called professional phagocytes
such as the polymorphonuclear granulocytes, the macrophages and monocytes. However,
the non-professional phagocytes, for instance the fibroblasts and epithelial cells, are also
able to uptake big particles under specific conditions (Rabinovitch 1995). Unlike
macropinocytosis, phagocytosis involves the recognition and binding of the cargo to
specific receptors. Recognition of particles lacking specific “eat me” signals on their
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surface occurs after their opsonisation (binding of immunoglobulins and other components
of the complement system). Actin-driven engulfment and internalization of the recognized
cargo results in phagosome formation. Phagosomes fuse to early and late endosomes and
form increasingly acidic phagolysosomes where the cargo is degraded by hydrolases and
other antimicrobial enzymes (Flannagan, Jaumouille & Grinstein 2012).
The fact that phagocytosis is mainly limited to specialized cell types has been
successfully utilized for the passive targeting of gene delivery systems. Microparticles of
the size of 1–10 μm, containing DNA vaccines, are too big for endocytosis by normal cells
but small enough for phagocytosis by antigen presenting cells such as macrophages or
dendritic cells (Little et al. 2005; Zhang et al. 2013). Phagocytosis, or a phagocytosis-like
mechanism, has also been shown to be involved in the uptake of large gene delivery
systems by non-professional phagocytes including airway epithelial cells (Matsui et al.
1997), fibroblasts (Santos et al. 2012), and retinal pigment epithelial cells (Vercauteren et
al. 2011b).
2.3.2 Macropinocytosis
Macropinocytosis is a larger-scale type of pinocytosis in which the plasma membrane
forms actin-driven protrusions, or ruffles, engulfing surrounding fluid. The resulting
vesicles, termed macropinosomes, are usually 0.2-10 μm in size. This type of endocytosis
is possible for any cell type, with only a few exceptions, and it is used for the massive
uptake of solutes (Doherty, McMahon 2009).
Macropinocytosis is generally believed to be induced by growth factors, although it
can also be induced by some viral and bacterial pathogens.  In some cell types, for
example in dendritic cells, macropinocytosis is a constitutive process not requiring
activation (Jones 2007). Conventional macropinocytosis occurs at the cell periphery and
does not require dynamin. However, a type of macropinocytosis called circular dorsal
ruffles has been shown to be dynamin-dependent (Orth et al. 2006). The formation of
circular dorsal ruffles has been observed in several cell types, including fibroblasts and
differentiated epithelial cells, in response to growth factor activation (Buccione, Orth &
McNiven 2004). The intracellular fate of macropinosome seems to vary between cell
types. In most cases, macropinosomes mature, acquiring early and late endosome markers,
and then fuse with lysosomes. However, in human epidermoid A-431 cells
macropinosomes do not contact with the endolysosomal system and recycle their contents
to the cell surface (Hewlett, Prescott & Watts 1994). In the human osteosarcoma cell line
macropinosomes stay intracellularly, without fusion with lysosomes or recycling
(Rintanen et al. 2012).
Macropinocytosis has been shown to be involved in the uptake and efficient transgene
expression mediated by cell penetrating peptides (Wadia, Stan & Dowdy 2004; Khalil et
al. 2006b; Al Soraj et al. 2012), lipoplexes (Pozzi et al. 2014), and PEI (Hufnagel et al.
2009). However, it must be noted that involvement of macropinocytosis in the gene
delivery process is difficult to study due to the lack of specific inhibitors as well as
characteristic membrane lipid or protein markers (El-Sayed, Harashima 2013).
22
Fi
gu
re
 4
.M
ai
n 
en
do
cy
tic
 p
at
hw
ay
s a
nd
 th
ei
r c
ha
ra
ct
er
is
tic
s.
23
2.3.3 Clathrin-mediated endocytosis
Clathrin-mediated endocytosis (CME) is one of the first discovered and most studied
endocytic pathways (McMahon, Boucrot 2011). It occurs in all mammalian cell types and
serves the continuous uptake of essential nutrients, antigens, growth factors, and receptors.
CME is a rapid and highly dynamic process, which is usually triggered by the ligand
binding to its specific receptor. With the help of adaptor and accessory proteins, of which
AP2 seems to be the most important, clathrin is recruited from the cytosol to the plasma
membrane where it forms hexagonal lattices. Polymerization of clathrin stabilizes the
membrane curvature and results in the formation of clathrin-coated pits that are separated
from the membrane by dynamin in an energy-dependent manner. The vesicles formed
usually have a diameter of 100-150 nm and undergo rapid uncoating, resulting in early
endosome formation. Upon endosome acidification, the receptors release ligands and are
usually transported back to the cell surface membrane. Ligands are sorted according to
their intracellular destinations, such as lysosomes, Golgi apparatus, or nucleus (Takei,
Haucke 2001; Doherty, McMahon 2009; McMahon, Boucrot 2011).
Gene delivery systems can be targeted to CME by the attachment of ligands to specific
receptors of which the transferrin and low-density lipoprotein (LDL) receptors are the
most widely used. CME can also occur in a nonspecific manner. Nonspecific CME is
involved in the internalization of carriers not coupled with any targeting moieties. As gene
delivery systems taken up by CME generally follow the endolysosomal pathway, it is
essential that they have an effective mechanism for endosomal escape. Therefore, a high
level of uptake by CME does not necessarily lead to high gene delivery efficacy. For
example, Rejman and co-workers demonstrated that although both PEI- and DOTAP-
based complexes entered HeLa (cervix epithelial carcinoma) and A549 (pulmonary
epithelial carcinoma) cells by CME, only in the case of DOTAP did this uptake pathway
result in high transgene expression (Rejman, Bragonzi & Conese 2005).
2.3.4 Caveolae-mediated endocytosis
Caveolae-mediated endocytosis (CavME) originates from lipid rafts of 60-80 nm in
size enriched with caveolin1 protein. The proteins termed cavins are essential for caveolae
formation and may function as coat proteins, stabilizing caveolae. CavME is dynamin-
dependent and is present in many cell types, including endothelial cells, adipocytes, and
fibroblasts, but it is absent in some cell types such as kidney proximal tubule cells (Parton,
Del Pozo 2013), lymphocytes, and neurons of the central nervous system (Razani,
Woodman & Lisanti 2002). In contrast to the rapidly internalizing clathrin-coated pits,
caveolae are very stable structures at the plasma membrane. In addition to their role in
endocytosis, they participate in lipid regulation and signalling.
CavME has attracted considerable attention in NP-mediated gene and drug delivery, as
it was long believed that cargo entering the cell by this pathway avoids lysosomal
degradation. However, it is now clear that caveolae fuse with endosomes, thus following a
conventional endocytic pathway (Sandvig et al. 2011; Parton, Del Pozo 2013). Caveolae
have been shown to be involved in the uptake and efficient gene delivery mediated by
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chitosan (Garaiova et al. 2012), PEI, DOTAP (Rejman, Bragonzi & Conese 2005;
Yamano et al. 2011), anionic PAMAM dendrimers (Perumal et al. 2008), and some other
carriers. However, the vast majority of these studies used chemical inhibitors (such as
filipin and genistein) and caveolae markers (such as shiga toxin and CTB), all of which
have lately been shown to be non-specific for the caveolae-mediated pathway (Iversen,
Skotland & Sandvig 2011; Vercauteren et al. 2012). In addition, some of the ligands (such
as lactosylceramide, a widely used specific marker of CavME) have been reported to
induce internalization of otherwise immobile caveolae (Sharma et al. 2004). Therefore, the
role of CavME in gene delivery might have been overestimated.
2.3.5 Flotillin-mediated endocytosis
Flotillin-mediated endocytosis (FME) was first reported in 2006. It occurs in lipid rafts
enriched with the FME specific proteins flotillins -1 and -2, but devoid of caveolin1.
Flotillins form microdomains in the plasma membrane of all studied mammalian cell
types. The dynamin-dependency of this pathway is unclear, and the studies in this field are
controversial (Otto, Nichols 2011). FME was reported to be responsible for the uptake of
GPI-linked proteins, proteoglycans, and partly of CTB. As with caveolae, flotillin-
enriched vesicles are internalized infrequently (Sandvig et al. 2011). They are believed to
fuse with late endosomes/lysosomes thereby directing their content to a conventional
endocytic pathway (Riento et al. 2009).
Several studies have demonstrated the involvement of FME in effective gene delivery.
Vercauteren et al. have shown that amidoamine polymer-based gene delivery systems are
internalized in retinal pigment epithelial cells by both FME and a phagocytosis-like
mechanism, but only the FME mediated pathway was beneficial in terms of transgene
expression (Vercauteren et al. 2011b). Other studies have demonstrated flotillin-mediated
uptake of silica NPs (Kasper et al. 2013) and pegylated polylysine-based delivery systems
(Chen et al. 2011).
2.3.6 Other clathrin-independent pathways
The CLIC/GEEC (clathrin-independent carrier/glycosylphosphatidylinositol (GPI)-
anchored protein-enriched endosomal compartments) endocytic pathway has been shown
to be involved in the uptake of GPI-anchored proteins, bacterial toxins, and extracellular
fluid (Doherty, McMahon 2009; Sandvig et al. 2011). In fibroblasts, CLIC/GEEC
endocytosis is responsible for at least half of the total fluid-phase uptake (Lundmark et al.
2008). It also plays an important role in cell spreading and migration (Doherty et al.
2011). This pathway requires the activity of small GTPases Cdc42 and Arf1, and is
dependent on cholesterol and actin polymerization. GRAF1 protein has been proposed as a
specific endogeneous marker (Lundmark et al. 2008), and cell-surface glycoprotein CD44
as a specific cargo for this pathway (Howes et al. 2010). Molecules endocytosed by
CLIC/GEEC pathway are delivered to early endosomes. Their further destination appears
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to be cell-type dependent, including both recycling endosomes and late
endosomes/lysosomes (Fivaz et al. 2002).
Another clathrin-independent pathway is Arf6-dependent endocytosis, which has been
found to be responsible for the uptake of major histocompatibility complex class I proteins
and some integrins. The interleukin2 (IL2) receptor was shown to enter cells by a distinct
endocytic pathway called RhoA-dependent endocytosis (Doherty, McMahon 2009;
Sandvig et al. 2011).
All these pathways are now being extensively studied. Their role in non-viral gene
delivery is not known due to their recent discovery and poor characterization.
2.4 Endocytosis in polarized cells and its role in gene delivery
So far, the vast majority of studies in the field of molecular biology involving
endocytosis have been performed in non-polarized cells (Sandvig et al. 2011). A few
studies in polarized epithelial and endothelial cells suggest differential localization and/or
regulation of endocytic processes in apical and basolateral compartments. In particular, a
predominant localization of caveolae on the basolateral membrane was found in
endothelial cells of retinal and brain capillaries (Gardiner, Archer 1986), as well as in the
MDCK (canine kidney epithelial) cell line (Vogel, Sandvig & van Deurs 1998). Although
clathrin-coated pits are present at both the apical and basolateral sides of MDCK cells,
they deliver their cargo to distinct intracellular compartments (Rodriguez-Boulan, Kreitzer
& Musch 2005), suggesting differential regulation of CME. Soluble factors, such as
proteinkinases A and C, were demonstrated to selectively stimulate clathrin-independent
endocytosis on the apical side of MDCK cells without affecting the basolateral uptake
(Eker et al. 1994). These experiments demonstrate that clathrin-independent endocytic
processes can also be subject to differential regulation.
Endocytosis is a first and critical step in transcytosis: the transport of macromolecular
cargo from one side of a cell to the other within membrane vesicles. This process is
believed to be of major importance in epithelial and endothelial cells as it mediates the
delivery of macromolecules through polarized cell barriers to the underlying tissue or
blood circulation. In vivo transcytosis has been documented in the endothelial cells of
heart, lung, skeletal muscle, and brain capillaries, as well as in the epithelial cells of
intestine, trachea, lung, thyroid, and some others. In addition, some other cell types, such
as bone-resorbing osteoclasts and neurons, are also capable of transcytosis (Tuma,
Hubbard 2003).
Although the regulation of transcytosis remains largely unknown, the endocytic
pathways involved seem to be highly dependent on the cell type. There is strong evidence
that the transcytosis of macromolecules through endothelial cells occurs by CavME. The
transendothelial transport of molecules, such as albumin, iron-transferrin, low density
lipoproteins, insulin, and chemokines, has been shown to involve caveolae (Frank,
Pavlides & Lisanti 2009; Wang et al. 2011). It has been proposed that in endothelial cells
the endocytic pathway dictates the intracellular fate of the endocytosed cargo.
Internalization by CME directs the cargo to lysosomal degradation, whereas caveolar
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uptake ensures transcytosis (Tuma, Hubbard 2003). In epithelial cells transcytosis seems
to be the branch of the conventional endocytic pathway mediated by CME. The best
example studied is the transcytosis of Immunoglobulin A (IgA) and its receptor by
epithelial cells in the intestine, kidney, and trachea (Tuma, Hubbard 2003).
Information about the involvement of endocytic pathways, other than CME and
CavME, in transcytosis is very scarce. For example, FME has been shown to be involved
in the transport of GPI-anchored proteins through polarized hepatocytes (Aït-Slimane et
al. 2009).
Detailed understanding of the endocytic processes in polarized cells and their
regulation can provide tools to improve the efficacy of gene delivery systems. The
targeting of gene delivery systems to the transcytotic pathway would allow crossing of the
endothelial and epithelial barriers on the way from the site of administration to the target
tissue. For example, gene delivery systems decorated with ligands targeted to insulin and
transferrin receptors, which are known to undergo transcytosis, have been shown to cross
the blood-brain barrier endothelial cells and deliver genetic material to the brain (Zhang,
Schlachetzki & Pardridge 2003; Shi et al. 2001). In contrast, the transcytotic pathway
should be avoided in gene therapy approaches where the endothelial and epithelial cells
are viewed not as a barrier, but as the target. For example, in gene therapy of hemophilia,
intestinal epithelial cells can be transformed to become platforms for the expression of
functional coagulation factors (Lozier et al. 1997); blood endothelial cells can be targeted
for gene therapy for stroke, atherosclerosis, and tumors (Mukerjee et al. 2011).
2.5 Experimental approaches to the study of endocytic pathways
of gene delivery systems
Studying the role of the endocytic pathway in NP-mediated delivery is a very
challenging task, as the uptake pathway is affected by multiple factors, such as particle
size, shape, surface charge, and ligand coupling, as well as the cell type. Besides, the same
particles have been shown to utilize more than one uptake pathway (Sahay, Alakhova &
Kabanov 2010; Iversen, Skotland & Sandvig 2011; Vercauteren et al. 2012).
Due to the lack of appropriate methodology for in vivo endocytosis studies, the vast
majority of data in the field has been generated in vitro. Although cell culture and isolated
tissue studies do not fully reconstitute a complex in vivo environment, especially the
signals provided by the vascular, nervous, and lymphatic systems, they can provide
fundamental information on the basic uptake and trafficking mechanisms of NPs in real-
time and at high resolution.
Currently available in vitro tools for the study of endocytic pathways can be roughly
divided into two groups:
 Inhibition studies, where one or several pathways are blocked by pharmacological
agents, gene silencing, or genetic manipulation of cell lines.
 Colocalization studies of NPs with specific endocytic pathways under normal (not-
blocked) conditions.
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The advantages and potential drawbacks of these methods will be discussed briefly in
the following chapters. (For a detailed review see: Sahay, Alakhova & Kabanov 2010;
Iversen, Skotland & Sandvig 2011; Vercauteren et al. 2012.)
2.5.1 Chemical inhibition of endocytosis
Blockage of endocytosis with pharmacological agents is the oldest, but still widely
used, approach for studying the role of the endocytic pathway in the delivery of NPs. This
approach has several advantages. It is relatively easy, cheap, and all cells in the culture
dish are equally affected by the treatment. As a short incubation period is usually
sufficient to achieve the blocking effect, the cells do not have time to develop delayed side
effects or compensatory mechanisms. However, this method has lately raised a lot of
concerns due to the toxicity, low specificity, and side effects of the chemical inhibitors
(Ivanov 2008; Iversen, Skotland & Sandvig 2011; Vercauteren et al. 2012). The
undesirable effects of chemical inhibitors can largely be attributed to their unspecific
interactions with multiple intracellular targets such as structural proteins, enzymes, and
lipids. For example, many of the currently used chemical inhibitors were shown to
interfere with the formation and distribution of F-actin fibers (Ivanov 2008). The actin
cytoskeleton plays a critical role in many intracellular processes, including cell motility,
division, signalling, and organelle and vesicular trafficking. Therefore, the preturbation of
the normal functioning of this protein results in multiple side effects, as well as in
unspecific blockage of all actin-dependent endocytic pathways. It must also be noted that
the performance of chemical inhibitors has been shown to vary between cell types
(Vercauteren et al. 2010). The inhibitors mostly used in NP studies, their mechanism of
action, and their main drawbacks are presented in Table 1.
When using chemical inhibitors one should remember, that (1) concentrations and
exposure time should be carefully optimized for each cell line in order to find the window
where inhibitors are efficient but do not exhibit significant toxicity and side effects, and
(2) inhibitor specificity to a particular endocytic pathway should be verified individually
for each cell line. In general, a combination with more modern approaches is highly
recommended in order to draw reliable conclusions (Iversen, Skotland & Sandvig 2011;
Vercauteren et al. 2010).
2.5.2 Genetic inhibition of endocytosis
Gene silencing. Blockage of the endocytic pathway can be achieved by silencing the
expression of key endocytic proteins by siRNA technology. This method is believed to be
more specific and less cytotoxic than chemical inhibitors. For example, siRNAs have been
used against the clathrin heavy chain (CHC), flotillin1, dynamin2, caveolin1, p21-
activated kinase 1 (Pak1) (Gabrielson, Pack 2009; Sahay et al. 2013; Vercauteren et al.
2011b; Al Soraj et al. 2012), Cdc42 and Rab1 (Sahay et al. 2013) to study the role of the
endocytic pathway in non-viral gene delivery. However, the selection of the target protein
requires detailed knowledge of the specific endocytic pathways at the molecular level.
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Additionally, most of the endocytosis-related proteins are known to be involved in more
than one pathway. Moreover, many proteins, including clathrin and caveolin, have other
functions in the cell unrelated to endocytosis (Brodsky 2012; Liu, Rudick & Anderson
2002). It must also be noted that the siRNA-mediated blockage of the endocytic pathway
usually takes 2-5 days. Therefore, the cells have time to adjust to the new condition, for
example by activating compensatory endocytic pathways. It has also been reported that
siRNA-mediated down-regulation does not occur equally in all cell populations. Another
concern is the efficacy and duration of the silencing after siRNA treatment. In addition,
the transfection agent used to deliver siRNA may cause side effects (Iversen, Skotland &
Sandvig 2011; Vercauteren et al. 2012).
Other genetic manipulations. One more tool that selectively perturbs one or more
endocytic pathways is the expression of mutant endocytosis-related protein that interferes
with the function of endogenous protein. Benmerah and co-workers transiently blocked
CME by transfecting cells with genetic construct coding for Epsin15 mutant lacking EH
domains (Benmerah et al. 1999). Similarly, Roy et al. used amino-terminal truncation
mutants of caveolin to perturb CavME (Roy et al. 1999). For a more controllable
expression, genetically manipulated stable cell lines can be generated. For example, a
DynK44A dominant-negative mutant was introduced to human epithelial carcinoma HeLa
cells to block dynamin-dependent endocytic pathways (Damke et al. 1994). Another
example is the hamster kidney fibroblast BHK cell line expressing CHC antisense RNA in
order to inhibit CME (Iversen et al. 2003). In these cell lines the blockage of endocytosis
can be induced by the removal of the antibiotic from the cell culture medium.
As with the gene silencing approach, this method is laborious, requires detailed
knowledge of the molecular biology of endocytosis, and may result in the activation of
compensatory endocytic mechanisms. In addition, abnormally high intracellular levels of
mutant protein may lead to low-affinity interactions, not observed under normal
conditions, and causing side effects and artefacts (Iversen, Skotland & Sandvig 2011).
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2.5.3 Fluorescent microscopy and other methods
Fluorescent microscopy is a widely used technique for the study of uptake and
intracellular trafficking of NPs, including gene delivery systems. In one approach, cells
are treated with fluorescently labelled NPs, fixed, and stained by immunocytochemistry
for pathway-specific or intracellular compartment-specific marker proteins (see Table 2
for examples). After imaging by confocal microscopy, colocalization analysis is
performed. Alternatively, colocalization studies can be performed in living cells. In this
case, prior to exposure to NPs, cells are transfected with genetic constructs encoding for
endocytosis-related proteins fused with fluorescent proteins like green fluorescent protein
(GFP) (Table 2). Such an approach avoids artefacts related to cell fixation and
permeabilization, and allows real-time imaging. However, possible artefacts related to
protein overexpression, including toxicity, aggregation, and low affinity interactions,
should be considered (Vercauteren et al. 2012).
Another way to study the endocytosis of NPs is through colocalization with marker
molecules with known uptake and/or trafficking pathways (Table 2). However, many of
these markers have been shown to utilize multiple endocytic pathways in the same cell,
and/or different pathways in different cell types. Therefore, for most of the pathways, no
specific marker is available at the moment. It must also be noted that electrostatic
interactions between cell membrane and cationic NPs often result in a significant surface-
bound fraction, which might be difficult to dissect from the intracellular fraction (Iversen,
Skotland & Sandvig 2011).
In general, low resolution is the common disadvantage of all fluorescent microscopy
methods. Parallel analysis of NP uptake by microscopic techniques with higher resolution,
such as atomic force microscopy, or different types of electron microscopy, can provide
more detailed information.
The activity of a specific endocytic pathway can be quantitatively estimated by
measuring the uptake of fluorescently labelled pathway-specific markers by flow
cytometry. As with fluorescent microscopy, special attention should be paid to verifying
the specificity of the markers and to the removal of cell surface-bound markers and NPs
(Iversen, Skotland & Sandvig 2011).
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3 Aims of the study
The general aim of this study was to evaluate the impact of the carrier and the endocytic
pathway on the non-viral gene delivery process and to improve the methodology used in
this type of study.
The more specific aims were:
1. To test the gene delivery properties of novel lysine-based dendrimers.
2. To clarify the impact of the carrier and endocytic pathway on cell uptake and the
intracellular kinetics of the introduced plasmid DNA.
3. To compare the genetic and chemical means of blocking endocytosis as tools for
studying the role of the endocytic pathway in nanoparticle-mediated gene delivery.
4. To suggest methods for endocytic characterization of endothelial and epithelial cell
lines utilized in nanoparticle uptake and transcellular permeation studies.
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4 Overview of materials and methods
Main materials used in the studies:
Material Description Source/Preparation
method
Publication
Plasmids
pCMV-nlslacZ Plasmid DNA containing
marker gene for bacterial
β-galactosidase modified
with the nuclear
localization signal
Provided
by B. Scholte (Erazmus
University, Rotterdam,
the Netherlands)
I
pCLuc4 Plasmid DNA containing
marker gene for luciferase
Provided
by Dr. F.C. Szoka
(UCSF, San-Francisco,
USA)
II
Gene delivery carriers
D5 Pentaspheric lysine
dendrimer
Synthesized at the
Institute of
Macromolecular
Compounds, St-
Petersburg, Russia
I
D5C10 Pentaspheric lysine
dendrimer modified at the
surface with capric acid
Synthesized at the
Institute of
Macromolecular
Compounds, St-
Petersburg, Russia
I
Polyfect Polyamidoamine
(PAMAM) cationic
dendrimer
Commercially available
(Qiagen)
I
PEI Polyethylenimine,
cationic polymer,
branched, 25kDa
Commercially available
(Sigma-Aldrich)
II
DOTAP
liposomes
1,2-dioleoyloxy-3-
(trimethylammonio)propa
ne –based cationic
liposomes
Prepared from
commercially available
lipid (Avanti Polar
Lipids)
II
CaP precipitates Prepared by calcium
phosphate
coprecipitation with
pDNA
II
Fluospheres, 200
nm
Fluorescently-labelled
polystyrene particles
Commercially available
(Molecular Probes)
III
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Cell lines
HeLa Human cervix epithelial
carcinoma cells
Cell culture collection
of the Institute of
Cytology, St.
Petersburg, Russia
I
HeLaK44A Human cervix epithelial
carcinoma cells with
inducible overexpression of
dynamin 2
Provided by Prof. K.
Sandvig (Institute for
Cancer Research at the
Norwegian Radium
Hospital, Oslo,
Norway)
II
BHK21tTA Hamster kidney fibroblasts
with inducible expression
of clathrin antisense RNA
hCMEC/D3 Human brain endothelial
cells
Provided by Dr. P.O.
Couraud (Institute of
Cochin, Paris, France)
III
CaCo-2 Human colon epithelial
carcinoma cells
ATCC (American
Type Culture
Collection)
III
Chemical inhibitors of endocytosis
Chlorpromazine Inhibitor of CME Commercially
available (Sigma-
Aldrich)
II
Monodansyl-
cadaverine
Inhibitor of CME Commercially
available (Sigma-
Aldrich)
II
Nystatin Inhibitor of caveolae/lipid
raft-mediated endocytosis
Commercially
available (Sigma-
Aldrich)
II
Dynasore Inhibitor of dynamin-
mediated endocytosis
Commercially
available (Sigma-
Aldrich)
II
Markers of endocytic pathways
Tf Fluorescently labeled
transferrin, marker of CME
Commercially
available (Molecular
Probes)
II, III
LacCer Fluorescently labeled
lactosylceramide, marker
of caveolae/lipid raft
mediated endocytosis
Commercially
available (Molecular
Probes)
III
Dextran Fluorescently labeled
polysaccaride, molecular
weight 10kDa, marker of
fluid phase uptake
Commercially
available (Sigma-
Aldrich)
III
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Methods used in the studies:
Study objective Method Publication
pDNA binding efficiency of gene
delivery carrier
Ethidium bromide displacement
assay
I
pDNA protection capacity of gene
delivery carrier
Resistance to DNase I
digestion test
I
Gene delivery complex size Dynamic light scattering II
Cytotoxicity MTT assay II
pDNA delivery (transfection) efficacy β-galactosidase activity assay I
Luciferase activity assay II
Cellular uptake of gene delivery
systems
qRT-PCR II
Quantification of nuclear-associated
pDNA
Nuclear isolation, qRT-PCR II
Blockage of endocytic pathways Chemical inhibitors II
Genetically manipulated cell
lines
II
Activity of endocytic pathways FACS-analysis II, III
Gene expression at the protein level Western blotting III
Gene expression at mRNA level qRT-PCR III
Protein intracellular localization Immunofluorescence III
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5 Lysine dendrimers as vectors for delivering genetic
constructs to eukaryotic cells
Reprinted with a permission from the publisher from: Kiselev A.V., Il’ina P.L., Egorova
A.A., Baranov A.N., Gur'janov I.A., Bayanova N.V., Tarasenko I.I., Lesina E.A., Vlasov
G.P., Baranov V.S. Lysine dendrimers as vectors for delivering genetic constructs to
eukaryotic cells. Russian Journal of Genetics 43(6):725-33, 2007.
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I
6 Genetic blockage of endocytic pathways reveals
differences in the intracellular processing of non-viral
gene delivery systems
Reprinted with a permission from the publisher from: Ilina P., Hyvonen Z., Saura M.,
Sandvig K., Yliperttula M., Ruponen M. Genetic blockage of endocytic pathways reveals
differences in the intracellular processing of non-viral gene delivery systems. Journal of
Controlled Release 163(3):385-395, 2012. Copyright 2012 Elsevier B.V.
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II
7 Effect of differentiation on endocytic profiles of
endothelial and epithelial cell culture models
Reprinted with a permission from the publisher from: Ilina P., Partti S., Niklander J.,
Ruponen M., Lou Y.R., Yliperttula M. Effect of differentiation on endocytic profiles of
endothelial and epithelial cell culture models. Experimental Cell Research 332(1):89–101,
2015. Copyright 2015 Elsevier B.V.
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III
8 Overview of the results
The main results reported in this thesis are summarized in the table below. More detailed
information can be found in the original publications.
Publication I: Novel lysine dendrimers as gene delivery carriers.
pDNA binding efficacy Lysine based dendrimers D5 and D5C10 completely
bound pDNA at DNA/carrier charge ratio 1/1 and 1/2,
respectively. The pDNA/dendrimer complex density
increased with the increasing amount of the carrier
pDNA protection efficacy The minimal DNA/carrier charge ratio ensuring
complete protection of pDNA against nuclease
degradation was 1/5 for D5 and 1/2 for D5C10
In vitro pDNA delivery
efficacy
The maximum pDNA delivery efficacy was 0.25% of
positive cells for D5 and 2.5% for D5C10
Effect of endosomolytic
peptide JTS-1 on the pDNA
delivery efficacy
JTS-1 increased the pDNA delivery efficacy by 1.5
times for D5 and 4 times for D5C10
Summary: Modification of lysine dendrimers with capric acid residues was
favourable for DNA binding and protective properties, and resulted in increased
delivery efficacy. The endosomolytic agent further improved the delivery efficacy of
the lysine dendrimers, however it still remained relatively low.
Publication II: Intracellular processing of non-viral gene delivery systems.
HeLaK44A cells BHK21tTA cells
pDNA cell uptake PEI>DOTAP>CaP PEI>DOTAP>CaP
pDNA nuclear association PEI>DOTAP>CaP PEI>DOTAP>CaP
Rate of cell-associated
(=intracellular+cell surface
bound)  pDNA elimination
CaP>DOTAP>PEI CaP>DOTAP>PEI
Transgene expression DOTAP >PEI~CaP DOTAP>PEI>CaP
Summary: Neither cellular uptake nor nuclear association of pDNA correlates with
transgene expression; transfection-limiting steps differ between carriers. Similar trends
were observed in two cell lines.
Publication II: Comparison of genetic and chemical approaches to block the
endocytic pathway.
Genetic block Chemical block
Effect on transfection
efficacy of non-viral gene
delivery systems
PEI: reduced
DOTAP: not changed, or
reduced (depending on the
cell line)
CaP: increased
PEI: reduced
DOTAP: reduced
CaP: reduced
78
Summary: In many cases similar trends were observed between the two methods.
However, chemical inhibitors resulted in a stronger inhibitory effect on transgene
expression than the usage of genetically manipulated cell lines. The most serious
discrepancies between the two approaches were observed for CaP precipitates.
Publication II: The role of the endocytic pathway in the cellular kinetics of non-viral
gene delivery systems.
HeLaK44A cells  with
blocked dynamin-
mediated endocytosis
BHK21tTA cells with
blocked CME
pDNA cell uptake Reduced for all carriers Reduced for all carriers
pDNA nuclear association PEI: reduced
DOTAP: not changed
CaP: increased
PEI: reduced
DOTAP: not changed
CaP: increased
Rate of cell-associated
(=intracellular+cell surface
bound)  pDNA elimination
PEI: reduced
DOTAP: increased
CaP: not changed
PEI: not changed
DOTAP: not changed
CaP: not changed
Transgene expression PEI: reduced
DOTAP: not changed
CaP: increased
PEI: reduced
DOTAP: reduced
CaP: increased
Summary: The effect of a specific blockage of either clathrin- or dynamin-dependent
endocytosis on transfection efficacy (=transgene expression) depends both on the
carrier and the cell type. Changes in transfection efficacy after genetic blockage of a
specific endocytic pathway correlated best with the level of nuclear-associated pDNA.
Publication III: Effect of differentiation on endocytic profiles of endothelial and
epithelial cell culture models.
CaCo-2 intestinal
epithelial cells
hCMEC/D3 brain
endothelial cells
Tightness and
differentiation status
Differentiated, tight
monolayer barrier with
low proliferation
Low differentiation,
multilayer, leaky barrier
Expression of the
endocytosis-related genes at
mRNA level during
differentiation
Decreased No change
Expression of the
endocytosis-related genes at
protein level during
differentiation
Correlated to the mRNA
levels in some, but not all
cases
Correlated to the mRNA
levels
Activity of endocytic
pathways during
differentiation
General endocytic
activity, CME and lipid
raft-mediated
endocytosis was reduced
No change
Nanoparticle uptake during
differentiation
Decreased No change
Comparison of endocytic No caveolin expression;  High PAK1 expression;
79
profiles of epithelial and
endothelial cell lines
Generally lower mRNA
expression of endocytosis
related genes
Generally higher mRNA
expression of endocytosis
related genes
Comparison of endocytic
profiles of cell lines to
primary cells
Discrepancies in expression of endocytosis-related
genes detected at both mRNA and protein level
Summary: Cell differentiation is correlated with a clear reduction in endocytosis;
mRNA levels of some endocytosis-related proteins are indicative of cell endocytic
activity. Differences in endocytic profiles were revealed between endothelial and
epithelial cells and also between cell lines and primary cells.
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9 General discussion
9.1 The role of the carrier in non-viral gene delivery
An “ideal” gene delivery carrier should fulfil many strict requirements. In particular, it
should be able to bind and compact nucleic acid to small particles, protect it from
undesirable interactions with biomolecules, deliver and release the cargo specifically to
the intracellular target site, and possess low toxicity (Pezzoli et al. 2012). The molecular
structure of the carrier is a key parameter affecting its gene delivery properties.
Developments in modern chemistry permit the synthesis of numerous compounds
potentially applicable for gene delivery purposes. Lysine dendrimers combine the benefits
of the dendritic structure, such as low polydispersity and ease of functionalization, with
the biodegradability of lysine (Boyd et al. 2006). In the publication I, we studied the gene
delivery properties of novel asymmetric lysine dendrimers: pentaspherical lysine
dendrimer D5 and its analog D5C10, modified with capric acid residues at the outer
sphere. Indeed, both molecules were able to bind and compact pDNA, protect it from
nuclease degradation, and deliver to the cell nuclei as was indicated by the transgene
expression. We demonstrated that modification of the dendrimer surface with capric acid
residues increased its DNA-binding and nuclease protective properties and its gene
delivery efficacy. Lipid modification has also been shown to improve the gene delivery
properties of other cationic polymers (Incani, Lavasanifar & Uludag 2010). This positive
effect may be attributed to the hydrophobic interactions between carrier molecules and
lipid membranes. The addition of endosomolytic peptide JTS-1 resulted in a considerable
increase of transfection efficacy, indicating that endosomal release is one of the important
transfection-limiting steps for lysine dendrimers. Low endosomal release has been also
demonstrated in experiments with other PLL-based carriers (Akinc, Langer 2002).
In our study, the efficacy of the lysine dendrimers did not exceed 15% of the treated
cells (when the endosomolytic peptide was used), whereas the efficacy of some viral
systems approaches 100%. Low transfection efficacy is a problem typical of non-viral
systems, including those based on lysine (Pezzoli et al. 2012). Although significant efforts
have been exerted to improve the efficacy of non-viral carriers, it must be noted that low
efficacy is sufficient, and is even desirable, in some applications, for example with DNA
vaccination (Chen, Huang 2005).
Overall, the data reported in the publication I demonstrate that lysine dendrimers can
be used as a basis for the development of more effective carriers. The superior gene
delivery properties of the modified over the unmodified dendrimer prove the validity of
the concept of modular multifunctional carriers. This concept suggests improving the gene
delivery properties of the basic carrier by the addition of certain blocks or complex
components targeted to overcome specific barriers (Sanvicens, Marco 2008). Further
illustrations indicating the validity of this concept for lysine dendrimers have been
provided by later studies performed by other groups. For example, PEG has been used to
improve the pharmacokinetics and biodistribution of lysine dendrimers upon in vivo
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administration (Kaminskas et al. 2008). In another study, the addition of a porphyrine core
resulted in an increased endosomal release of the lysine dendrimer-based carrier (Ma et al.
2013).
So far, the search for an optimal non-viral carrier has been based mainly on the trial-
and-error principle. This approach has shown itself to be highly inefficient in terms of
cost, time and outcomes. Although thousands of compounds have been tested during
recent decades, the number of non-viral carriers that demonstrate an efficacy comparable
to that of the viral vectors is negligible, and none of the non-viral agents is currently
approved for clinical use. Building up quantitative structure-activity relationships is
promising as a potent approach, enabling a more rational carrier design. However, a
comparison of the results obtained in the different studies reported in the literature is
limited by the great diversity of carrier structures and methods. From this perspective,
parallel studies of structurally related compounds, similar to our comparison of the
unmodified dendrimer with its modified analog, are of especially great value. Indeed, the
transfection-favorable structural features of lipids (Ivanova et al. 2013), dendrimers
(Kwok et al. 2013; Li et al. 2014), and some other groups of carriers has recently been
revealed through this approach. Modern, high-throughput screening technologies are able
to increase the speed and efficiency of analysis. It should be possible to perform
simultaneous screenings of multiple compounds for such parameters as complex
formation, pDNA release, cytotoxicity, and transfection efficacy (Rinkenauer et al. 2013).
Moreover, comparative studies on cellular uptake and intracellular trafficking would allow
the determination of the structural features of the carrier that are critical for improved
penetration via distinct intracellular barriers. Based on these data, more specific structure-
activity relationships could be established.
In the publication II, we studied in greater detail the relationship between the carrier
and its delivery efficacy. In particular, we questioned how the carrier affects cell uptake
and intracellular processing of genetic material (pDNA). For this study we selected three
carriers: cationic polymer PEI, cationic lipid DOTAP, and CaP co-precipitated with
pDNA, all of which are widely used in gene delivery studies. We applied a highly
sensitive qRT-PCR based method to quantify the amount of cell-associated and nuclear-
associated pDNA at multiple time points. The data obtained was correlated to the
transfection efficacy of the carrier as indicated by the reporter protein expression. In
contrast to our study, in most of the published studies, the analysis of the intracellular
kinetics of pDNA has been performed by the semi-quantitative method of fluorescent
microscopy, with transfection efficacy estimated only at a single time point.
Cell uptake was efficient for all the carriers, and seemed not to be a transfection-
limiting step. The amount of internalized pDNA varied between carriers, but did not
correlate with transgene expression. We suggest that positively charged gene delivery
systems bind non-specifically to various negatively charged cell surface molecules, which
results in internalization by multiple endocytic pathways. This is especially true for the
high dose gene delivery systems, typically used for in vitro experiments, and should be
taken into account when extrapolating in vitro data to the in vivo situation where the doses
reaching target cells are generally low.
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The elimination of cell-associated pDNA differed drastically between the carriers,
being the fastest for the CaP- and the slowest for the PEI-mediated gene delivery. The
same trend was observed in both the cell lines studied in this work, as well as in other cell
lines (Ruponen et al. 2009; Billiet et al. 2012; Nomani et al. 2014), indicating that pDNA
elimination rate is carrier rather than the cell line dependent. The rapid degradation of
pDNA after the CaP-mediated transfection resembled the elimination of naked DNA and
most likely resulted from the inability of CaP to protect pDNA from enzymatic
degradation.
Furthermore, we compared the amount of pDNA delivered to the nucleus by different
carriers. As with the cell uptake data, the nuclear delivery of pDNA varied between
carriers, but showed no correlation with transfection efficacy. The data obtained was in
line with the literature as several groups showed no correlation between either cellular or
nuclear uptake of pDNA and the transfection efficacy of various polymer- and lipid-based
carriers (Cohen et al. 2009; Ruponen et al. 2009; Hyvonen et al. 2012; Billiet et al. 2012).
To the best of our knowledge, this was not studied earlier for CaP precipitates. The lack of
correlation between nuclear delivery and transfection efficacy can be explained by the
insufficient release of pDNA from the carrier, as well as by carrier interaction with various
endogenous molecules. Cationic carriers were indeed shown to disturb transcription and/or
translation of genetic material (Hama et al. 2007). Highly positively charged polymers,
such as PEI, seem to affect the processing of genetic material to a greater extent than lipid-
based cationic carriers such as DOTAP. Our studies indicate the importance of postnuclear
processes as a barrier in non-viral gene delivery. Future studies should pay more attention
to the biocompatibility of the carrier. In particular, the use of biodegradable carriers might
help to avoid the problem. In general, the results obtained indicate that the carrier affects
cell uptake and the intracellular kinetics of the introduced genetic material and,
furthermore, predetermines the main transfection-limiting step, which seems to be the
rapid elimination of cell-associated pDNA in CaP-, prenuclear transport in DOTAP-, and
postnuclear events in PEI-mediated transfections.
9.2 The role of the endocytic pathway in non-viral gene delivery
The endocytic pathway is currently believed to play a critical role in the gene delivery
process as it is linked to intracellular trafficking and the final destination of the
endocytosed cargo. Although gene delivery systems can enter cells by many endocytic
pathways, it has been shown that some pathways result in higher gene delivery efficacy
than others (Rejman, Bragonzi & Conese 2005; Douglas, Piccirillo & Tabrizian 2008;
Gabrielson, Pack 2009; Vercauteren et al. 2011b). By now, it is clear that for carriers of
different structure different pathways can be beneficial. During the last decade,
considerable effort has been devoted to obtaining a more detailed understanding of the
underlying mechanisms; however, we are still far from the complete picture.
As reported in publication II, we performed a systematic study of the role of specific
endocytic pathways in gene delivery mediated by PEI, DOTAP and CaP precipitates. The
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impact of clathrin- and dynamin-dependent endocytosis on cell uptake, and cell-associated
pDNA elimination and transport to the nucleus, were evaluated quantitatively in two
genetically manipulated cell lines with inducible blockage of these pathways. Blocking of
CME in the genetically manipulated BHK (hamster kidney fibroblast) cell line was
induced by the expression of antisense RNA to the clathrin heavy chain protein. Blocking
of the dynamin-dependent endocytosis in the genetically manipulated HeLa (human
epithelial carcinoma) cell line resulted from the inducible expression of mutant dynamin1.
It should be noted that dynamin-dependent endocytosis is a group of pathways including
CME, CavME and some other, less characterized endocytic mechanisms.
Blocking of either the CME or dynamin-dependent endocytosis decreased the cellular
uptake of all gene delivery systems studied. This result was not surprising, as positively
charged gene delivery systems are known to utilize multiple endocytic pathways due to
their ability to electrostatically and non-specifically bind to negatively charged plasma
membrane (Vercauteren et al. 2012). Interestingly, in the case of the CaP precipitates, the
lower pDNA uptake in the cells with blocked endocytic pathways resulted in greater
reporter protein expression indicating possible activation of alternative endocytic
pathways favourable for this carrier. Indirect evidence of alternative pathway activation
upon genetic blockage of endocytosis has been reported previously in the literature
(Damke et al. 1994).
The elimination of cell-associated pDNA was little changed after the blockage of
endocytosis. This probably results from the fact that practically all known pathways are
known to direct their cargo to the endolysosomal compartment with high nuclease activity
(El-Sayed, Harashima 2013). Moreover, intracellular pDNA can also be degraded by
cytoplasmic nucleases after complex release to the cytoplasm (Sasaki, Kinjo 2010). We
conclude that intracellular pDNA elimination does not correlate to the changes observed in
reporter protein expression upon blockage of endocytosis, and seems not to be an
informative parameter when determining the endocytic pathway most beneficial for gene
delivery. In contrast, the amount of pDNA transported to the nucleus in the blocked versus
the not-blocked cells demonstrated good correlation with transfection efficacy in most
cases.
Finally, we aimed to study the role of specific endocytic pathways in the overall
transfection efficacy of gene delivery systems. In line with other studies, we confirmed
that the uptake pathway most beneficial for transfection depends on both the carrier and
the cell type. We demonstrated the important role of CME in DOTAP- but not in PEI-
mediated gene delivery in the BHK cell line, and the more important role of dynamin-
mediated endocytosis in PEI- than in DOTAP-mediated gene delivery in HeLa cells. The
literature reports on the relative importance of different endocytic pathways in effective
transfection are rather controversial. For example, CME (von Gersdorff et al. 2006),
macropinocytosis (Hufnagel et al. 2009), and clathrin-independent pathways (Rejman,
Bragonzi & Conese 2005; Gabrielson, Pack 2009) have all been suggested as being critical
for PEI-mediated transfection. One of the main reasons for the controversy observed in the
field is the diversity of the data in terms of the carriers used, the cell lines, and the
experimental methods (Vercauteren et al. 2012), all of which make comparisons between
different studies and the drawing of general conclusions challenging. In subsequent
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studies we addressed some of these methodological problems, which will be discussed in
greater detail in chapter 9.3.
9.3 Improving experimental methodology in cell uptake studies
9.3.1 Searching for an optimal approach to block the endocytic pathway
Selective blockage of endocytosis is a valuable tool when studying the role of the
endocytic pathway in gene delivery. According to the literature, pathway-specific
chemical inhibitors have been the most frequently used approach in blocking endocytosis.
However, the specificity and the side effects of chemical inhibitors have raised serious
concerns in the scientific community (Ivanov 2008; Iversen, Skotland & Sandvig 2011;
Vercauteren et al. 2012). Genetically modified cell lines provide more specific and less
cytotoxic alternatives. Although this approach has been used in virus uptake studies
(Wang et al. 1998; Lakadamyali, Rust & Zhuang 2004), we were the first to use it in the
non-viral gene delivery field.
Our studies showed that genetically manipulated cell lines with inducible blocking of
endocytosis provide a useful tool for non-viral gene delivery studies. In most cases the
chemical inhibitors and genetically modified cell lines demonstrated similar trends.
However, some discrepancies were also revealed. In particular, the chemical inhibitors
resulted in a stronger inhibition of transgene expression when compared with the
genetically modified cell lines. Moreover, in the case of CaP precipitation, the two
methods demonstrated opposite trends. The observed discrepancies may be attributed to
the side effects of the inhibitors as well as to the possible activation of alternative
endocytic pathways in the genetically blocked cells. Our study, together with studies done
by others (Iversen, Skotland & Sandvig 2011; Vercauteren et al. 2012), provide strong
evidence that, to date, none of the methods is ideal, all being a combination of benefits and
drawbacks. More specific and targeted inhibitors of endocytosis are urgently needed.
Computational tools, enabling the prediction of biological targets for chemical
compounds, and high-throughput screening of chemical compound libraries are promising
strategies for identification of new specific chemical inhibitors of endocytosis (Ivanov
2014). Moreover, increased knowledge about the regulators of endocytosis will make
possible the generation of new mutant cell lines with disrupted functioning of endocytosis-
related genes and improved gene silencing protocols.
9.3.2 Endocytic profiling of cell models
Studies on the role of the endocytic pathway in gene delivery have been performed in
multiple cell culture models. In many studies it has been assumed that all pathways are
present in all cell types. However, it is now becoming clear that different cell types are not
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equal with respect to the expression and activity of endocytic pathways. For example,
morphological data reveal the presence of particularly high numbers of caveolae in some
cell types, including the adipocytes and endothelial cells (Razani, Woodman & Lisanti
2002). In contrast, no caveolae have been found in lymphocytes or the neurons of the
central nervous system (Razani, Woodman & Lisanti 2002). Expression of flotillins -1 and
-2 also varies between cell types (Volonte et al. 1999), although it is not yet clear how
observed differences are related to the presence and activity of FME. Overall, the
information available on the presence and activity of endocytic pathways in different cell
types is still very fragmented. We suggest that detailed characterization of cell lines in
terms of functional endocytic pathways (endocytic profiling) would significantly facilitate
interpretation of the data on the uptake and cellular processing of NPs. In addition, the
question of how faithfully in vitro models recapitulate in vivo endocytic processes should
be more carefully addressed.
Endothelial and epithelial cells create a substantial barrier for gene delivery systems
administered by all routes except by direct injection into target tissue. These cells are
widely used in NP uptake studies and therefore represent an interesting subject for
endocytic profiling. In vivo these cell types are highly differentiated. It has been reported
that the differentiation is accompanied by a reduced endocytic activity of both fluid uptake
markers and NPs (Matsui et al. 1997; Foerg et al. 2007; O'Neill et al. 2011). However, the
effect of differentiation on specific endocytic pathways has not been addressed.
In the study III we performed endocytic profiling of CaCo-2 cells modelling intestine
epithelium and hCMEC/D3 cells modelling brain endothelium, and compared them to
primary cells. Moreover, we studied how cell endocytic profiles are dependent on cell
differentiation.
Differentiation of CaCo-2 cells was accompanied by a very significant reduction of
mRNA expression of most endocytosis-related genes, and a reduction in uptake of
endocytic markers and NPs. In contrast, brain endothelial cells were poorly differentiated,
demonstrated no major changes in the mRNA expression of endocytosis-related genes,
and retained significant endocytic activity. Our studies emphasize that the differentiation
status of in vitro cell models should be taken into account when designing NP permeation
experiments.
The lack of correlation between the cell lines and the corresponding primary cells for
some endocytosis-related proteins was demonstrated. In particular, the mRNA expression
profile for endocytosis-related genes in CaCo-2 cells was lower than in the primary cells.
In the hCMEC/D3 cells the opposite trend was observed. These differences may, at least
partially, arise from the cancerous/immortalized nature of in vitro models. For example, an
overexpression of both caveolin and clathrin heavy chain in hepatic cancer, in comparison
to normal cells, has been reported (Tse et al. 2012; Seimiya et al. 2008). The physiological
relevance of the data obtained in the immortalised cell lines is a question of debate in the
literature (Bouis et al. 2001). Although primary cells are generally believed to be more
representative of the in vivo situation, they are known to lose their initial properties soon
after isolation (Lacorre et al. 2004), and their properties may vary between isolations
(Bouis et al. 2001). Further development of a methodology for in vivo endocytosis studies
would help to answer the question of the representativity of continuous cell lines and
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primary cells. Moreover, this would shed light on the cellular processing of NPs in the
living body. Conventional electron microscopy and immunofluorescence techniques of
fixed tissue samples do not take into account the highly dynamic nature of the endocytic
processes. Recent developments in intravital microscopy have allowed the visualization of
cell uptake and the distribution of fluorescently labelled molecules in living animals
(Sandoval, Molitoris 2008). Although insufficient tissue penetration, low resolution, and
high costs remain serious limitations for this technique, it definitely has great potential for
in vivo uptake studies of therapeutic NPs.
In our work, we emphasize the importance of the endocytic profiling of cell lines prior
to studies on the cellular processing of therapeutic NPs. The most straightforward method
for endocytic characterization of the cell lines is through a direct measurement of the
endocytic uptake of pathway-specific markers. The characteristics of an ideal endocytic
marker would include (1) specificity to one or several endocytic pathways, (2) lack of
stimulation of the target pathway or other pathways, and (3) low toxicity. Although Tf is
considered to be relatively specific for CME, well-established markers for other pathways
are currently lacking. SV40, CTB and LacCer have been suggested as markers for
caveolae-mediated endocytosis. However, SV40 was later shown to enter cells also by
CME; CTB was demonstrated to utilize multiple pathways within the same cell type
(Torgersen et al. 2001); and LacCer seems to be a marker of many clathrin-independent
pathways (Hansen, Nichols 2009) as is also indicated by our data. Moreover, LacCer has
been shown to stimulate caveolar uptake (Sharma et al. 2004). The discovery of new
molecules that are taken up by specific endocytic pathways is an extremely important
direction for future research.
Taking into account the current lack of pathway-specific markers, we suggest that the
mRNA expression of endogenous proteins involved in certain endocytic pathways can be
indicative of the expression and activity of those pathways. This novel approach is
relatively cheap and fast, and could therefore be routinely utilized for the screening of cell
lines for the presence of specific endocytic pathways prior to studies on the cellular
processing of therapeutic NPs. A comparison of the endocytic profiles of cell lines with
those of primary cells and human- and animal-derived tissues would allow the selection of
the most representative in vitro models. Several important factors must be considered
when discussing the feasibility of this approach. Firstly, mRNA levels do not necessarily
correlate with the actual protein levels. Secondly, for proteins with multiple functions in
the cell (such as the protein kinases included to our study), high protein levels do not
necessarily suggest high activity of the corresponding endocytic pathway. The data
obtained in our studies indicate that the mRNA expression of some proteins (caveolin1
and flotillin2) have the potential to be used as pathway activity markers. Further studies
are needed to firmly establish this method.
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10 Conclusions
This thesis provides insight into the role of the carrier and the endocytic pathway in non-
viral gene delivery. Furthermore, the reported studies contribute to improvements in the
methodology used in the field. The main conclusions are as follows:
1. Lysine dendrimers are able to bind and compact pDNA, protect it from nuclease
degradation, and deliver it to cell nuclei. Although modification with capric acid and the
utilisation of an endosomolytic agent improve the gene delivery properties, transfection
efficacy is generally low. Lysine-based dendrimers can be used as a basis for the
development of more effective carriers.
2. Neither the cellular, nor nuclear uptake of cationic delivery systems correlates with
transgene expression. Post-nuclear processes are an important barrier in non-viral gene
delivery.
3. The main transfection-limiting intracellular step of the non-viral gene delivery system is
strongly carrier-dependent and seems to be the rapid elimination of cell-associated pDNA
in CaP-, pre-nuclear transport in DOTAP-, and post-nuclear events in PEI-mediated gene
delivery.
4. The endocytic pathway most beneficial for gene delivery is both carrier and cell type
dependent. Neither the amount of pDNA taken up by the cell, nor the intracellular pDNA
elimination, but only the amount of pDNA delivered to the nucleus is indicative of the
significance of the particular pathway in the ultimate delivery efficacy of the particular
carrier.
5. Genetically manipulated cell lines can be used as a tool to specifically block
endocytosis in gene delivery studies. A comparison of chemical and genetic means to
block endocytosis revealed the limitations of both those methods. Careful method
optimization, and parallel studies using several alternative approaches, are recommended
in order to obtain more reliable data.
6. The expression and activity of endocytic pathways are dependent on the cell type and
the differentiation stage of the cell. Performing cell line characterization for the expression
and activity of endocytic pathways (endocytic profiling) could facilitate the interpretation
of data on the cellular processing of gene and drug delivery systems.
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11 Future prospects
The clinical significance of biopharmaceuticals, including the peptides, recombinant
therapeutic proteins, and nucleic acids is increasing. The number of peptide- and protein-
based products launched onto the market is high and is constantly growing (Mitragotri,
Burke & Langer 2014). Although nucleic acid-based products are generally at an early
stage of development, the first gene therapy drugs have been approved for clinical use
(Wirth, Parker & Yla-Herttuala 2013). The structural complexity of biopharmaceuticals
assures their high specificity and potency as compared to conventional small drug
molecules, but it also creates multiple challenges in their formulation and delivery.
As the successful delivery of macromolecular drugs is critically dependent on the
carrier, the development of new carriers, including those for non-viral gene delivery, will
remain an active area of research. The design of more effective carrier molecules should
be more rational and not based on the trial-and-error principle. One of the prospective
directions for future studies is the building of quantitative structure-activity relationships
in order to relate the efficacy of every step of the delivery process to the molecular
architecture of the carrier. Advances in computational modelling, combinatorial chemical
synthesis, and the high throughput screening of libraries of chemical compounds will all
help to identify potential highly effective carriers.
Due to their large size, the pharmacokinetics of macromolecular drugs is drastically
different from that of small molecules. The main mechanism for small drug molecules to
be absorbed and distributed inside the body is passive transcellular diffusion, whereas, for
biological drugs, it is the endocytosis-based mechanisms. During recent decades the
endocytic pathways and the subsequent intracellular trafficking of many macromolecular
drugs, including gene delivery systems, have been described for various cell types. How
the intracellular fate of the delivery systems can be controlled by their properties is
another important question to be answered. Progress in this field will be further facilitated
by new findings in fundamental cell biology, as well as by the further development of
experimental tools. In particular, more specific markers and inhibitors of endocytosis are
greatly needed.
Most of the currently available data on the mechanisms of drug and gene delivery have
been obtained in cell and tissue cultures. The relevance of the models utilized to the
physiological conditions is of utmost importance and should be addressed in a more
careful and systematic manner. The characterization of existing cell models and the
development of new models that represent the in vivo situation better should definitely be
the focus of future research. Because of the importance of endocytosis in the
pharmacokinetics of biological drugs, it is necessary to characterize not only the target
cells but also the cells composing the biological barriers on the way to the target tissue.
Additionally, in vivo studies on cell uptake and the intracellular trafficking of
macromolecular drugs would provide extremely valuable information. The development
of appropriate methods, including intravital microscopy, is currently in progress.
The huge amount of work performed in recent decades by researches all over the world
has significantly improved our understanding of the critical parameters for the successful
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delivery of macromolecular drugs. However, many pieces of the puzzle are still missing.
We strongly believe that future studies will help to build a more comprehensive picture of
the delivery process of macromolecules, and will allow the development and clinical
approval of new potent macromolecular medicines, including non-viral gene therapy
products.
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